Find tests predicting disease progression
- Trial ID
- NCT05266872
- Official Title
- Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)
- Goal
- Find tests predicting disease progression
- Status
- RECRUITING
- Sponsor
- Luxembourg Institute of Health
- Study Type
- OBSERVATIONAL
- Enrollment
- 1800 participants
- Conditions
- Parkinson Disease
- Interventions
- Observational study with sample and data collection
Plain-Language Summary
The goal is to create a large, well-characterized biobank of blood, spinal fluid, skin and other samples linked to clinical data so researchers can find biomarkers, understand what drives Parkinson's, and track disease progression. Participants give samples and health information, with procedures that can include blood draws, optional lumbar puncture for cerebrospinal fluid, and skin biopsies, so scientists can look for molecules or changes that predict diagnosis, course, or treatment response. People 18 and older with typical Parkinson's or atypical parkinsonism who can consent, or who have an authorized representative, can join, while those with active cancer, pregnancy, refusal to consent, or bleeding problems that make biopsies or lumbar puncture unsafe are excluded.
Locations
- Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic", Luxembourg, Luxembourg
- Clinical and Epidemiological Investigation Center (CIEC), Luxembourg, Luxembourg
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Observational study with sample and data collection. The goal is to create a large, well-characterized biobank of blood, spinal fluid, skin and other samples linked to clinical data so researchers can find biomarkers, understand what drives Parkinson's, and track disease progression. Participants give samples and health information, with procedures that can include blood draws, optional lumbar puncture for cerebrospinal fluid, and skin biopsies, so scientists can look for molecules or changes that predict diagnosis, course, or treatment response. People 18 and older with typical Parkinson's or atypical parkinsonism who can consent, or who have an authorized representative, can join, while those with active cancer, pregnancy, refusal to consent, or bleeding problems that make biopsies or lumbar puncture unsafe are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 11 years.